TABLE 3 | Selected compounds affecting T-cell-activation pathways
From the following article:
Targeting signal transduction as a strategy to treat inflammatory diseases
Luke A. J. O'Neill
Nature Reviews Drug Discovery 5, 549-563 (July 2006)
doi:10.1038/nrd2070
| Compound | Structure | Target | Comments | Refs |
|---|---|---|---|---|
| ISA247 | ![]() | Calcineurin | Phase III clinical trials for psoriasis | 50 |
| FTY720 | ![]() | Sphingosine-1-phosphate receptor | Phase III clinical trials for multiple sclerosis | 53 |
| Rapamycin | ![]() | mTOR | Approved for transplantation | 54 |
| Everolimus | ![]() | mTOR | Phase II clinical trials for rheumatoid arthritis | 57 |
| Temsirolimus | ![]() | mTOR | Phase II clinical trials for multiple sclerosis | 58 |
Download file
If the slide opens in your browser, select "File > Save As" to save it.





